Trigo José Manuel, Panayi Fany, Soria Guadalupe, Maldonado Rafael, Robledo Patricia
Universitat Pompeu Fabra, Calle Dr. Aiguader, 80, 08003, Barcelona, Spain.
Psychopharmacology (Berl). 2006 Jan;184(2):212-20. doi: 10.1007/s00213-005-0229-7. Epub 2005 Dec 15.
MDMA is one of the most widely consumed recreational drugs in Europe. However, the mechanisms involved in the reinforcing properties of MDMA are still unclear. In this sense, the establishment of a reliable model of MDMA self-administration in mice could represent an important approach to study the neuronal substrates associated with MDMA reward by using genetically modified mice.
To develop a reliable model of operant intravenous MDMA self-administration in drug-naïve mice.
Mice were trained to acquire intravenous self-administration of MDMA at different doses (0, 0.06, 0.125, 0.25, 0.5 and 1.0 mg/kg/infusion) on a FR1 schedule of reinforcement for 15 consecutive days. The motivational value of different doses of MDMA (0.125, 0.25 and 0.5 mg/kg/infusion) was then tested using a progressive ratio paradigm. Finally, [3H]-mazindol autoradiographic studies were carried out in order to quantitatively assess presynaptic dopamine transporter (DAT) binding sites in the striatum of mice trained to self-administer MDMA (0 and 1.0 mg/kg/infusion) during 15 days.
The latency for discrimination between the active and inactive holes, as well as the number of animals acquiring stability criteria, varied as a function of the dose of MDMA. The mice responding for intermediate doses (0.125, 0.25 and 0.5 mg/kg/infusion) discriminated earlier than those responding for low (0.06 mg/kg/infusion) or high (1.0 mg/kg/infusion) doses. The percentage of animals achieving stability criteria increased with days of testing and was inversely proportional to the dose of MDMA. The breaking points achieved for doses of 0.125 and 0.25 mg/kg/infusion were significantly higher than for a dose of 0.5 mg/kg/infusion. No significant DAT neurotoxicity was observed in the striatum of animals self-administering MDMA at a dose of 1 mg/kg/infusion.
The present results show that MDMA can be reliably self-administered by drug-naïve mice.
摇头丸是欧洲消费最广泛的消遣性毒品之一。然而,摇头丸强化特性所涉及的机制仍不清楚。从这个意义上讲,建立一种可靠的小鼠摇头丸自我给药模型可能是通过使用基因改造小鼠来研究与摇头丸奖赏相关的神经元基质的重要方法。
在未接触过药物的小鼠中建立一种可靠的操作性静脉注射摇头丸自我给药模型。
对小鼠进行训练,使其在固定比率1(FR1)强化程序下连续15天以不同剂量(0、0.06、0.125、0.25、0.5和1.0毫克/千克/输注)进行静脉注射摇头丸的自我给药。然后使用渐进比率范式测试不同剂量摇头丸(0.125、0.25和0.5毫克/千克/输注)的动机价值。最后,进行[3H]-吗茚酮放射自显影研究,以定量评估在15天内接受摇头丸(0和1.0毫克/千克/输注)自我给药训练的小鼠纹状体中突触前多巴胺转运体(DAT)结合位点。
主动孔和非主动孔之间的辨别潜伏期以及达到稳定标准的动物数量随摇头丸剂量而变化。对中等剂量(0.125、0.25和0.5毫克/千克/输注)做出反应的小鼠比那些对低剂量(0.06毫克/千克/输注)或高剂量(1.0毫克/千克/输注)做出反应的小鼠更早辨别出来。达到稳定标准的动物百分比随测试天数增加,并且与摇头丸剂量成反比。0.125和0.25毫克/千克/输注剂量的断点显著高于0.5毫克/千克/输注剂量。在以1毫克/千克/输注剂量自我给药摇头丸的动物纹状体中未观察到明显的DAT神经毒性。
目前的结果表明,未接触过药物的小鼠可以可靠地自我给药摇头丸。